Atrasentan, CAS 173937-91-2

Product Description: Atrasentan (ABT-627) is an endothelin receptor antagonist with IC50 of 0.0551 nM for ETA[1].

Applications: Metabolism-protein/nucleotide metabolism

Formula: C29H38N2O6S

Citations: Commun Biol. 2022 Jul 28;5(1):750./Eur J Pharmacol. 2019 Mar 12;852:142-150./Department Veterinary Clinical Medicine. University of Illinois. 2015./J Vet Intern Med. 2015 Nov;29(6):1584-94./Mol Immunol. 2019 Oct;114:10-18. 

References: [1]Yuyama H, et al. Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist. Eur J Pharmacol. 2004 Sep 13;498(1-3):171-7./[2]Banerjee S, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res. 2007 Apr 15;67(8):3818-26./[3]Weiss J, et al. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro. Cancer Chemother Pharmacol. 2011 Oct;68(4):1093-8.

CAS Number: 173937-91-2

Molecular Weight: 542.69

Compound Purity: 99.58

Research Area: Cancer; Endocrinology; Cardiovascular Disease

Solubility: DMSO : 100 mg/mL (ultrasonic)

Target: Endothelin Receptor

• SKU: MEXHY-15403-10.1
• Manufacturer: MedChemExpress
• Manufacturer SKU: HY-15403-10.1
• Package Unit: 10 mM/1 ml
• Quantity Unit: STK